Megan L Salter1, Bryan Lau, Shruti H Mehta, Vivian F Go, Sean Leng, Gregory D Kirk. 1. *Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, MD; †Johns Hopkins University Center on Aging and Health, Baltimore, MD; Divisions of ‡Geriatric Medicine; and §Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: HIV and hepatitis C virus (HCV) infections may increase interleukin-6 (IL-6) and C-reactive protein (CRP). However, relationships between inflammatory biomarkers, chronic viral infections, clinical factors, and behavioral factors remain poorly understood. METHODS: Using linear regression, we modeled cross-sectional associations between loge IL-6 or loge CRP levels and HCV, HIV, injection drug use, and comorbidity among 1191 injection drug users. RESULTS: Mean age was 47 years, 46.0% reported currently injecting drugs, 59.0% were HCV monoinfected, and 27% were HCV/HIV coinfected. In multivariable models, higher loge IL-6 was associated with HCV monoinfection [β = 0.191, 95% confidence interval (CI): 0.043 to 0.339] and HCV/HIV coinfection (β = 0.394, 95% CI: 0.214 to 0.574). In contrast, HCV monoinfection (β = -0.523, 95% CI: -0.275 to -0.789) and HCV/HIV coinfection (β = -0.554 95% CI: -0.260 to -0.847) were associated with lower CRP. Lower CRP with HCV infection was independent of liver fibrosis severity, synthetic function, or liver injury markers; CRP decreased with higher HCV RNA. Increased injection intensity was associated with higher IL-6 (P = 0.003) and CRP (P < 0.001); increasing comorbidity (P < 0.001) and older age (P = 0.028) were associated with higher IL-6; older age was associated with higher CRP among HCV-uninfected participants (P = 0.021). CONCLUSION: HIV and HCV infections contribute to chronic inflammation; however, reduced CRP possibly occurs through HCV-mediated mechanisms. Findings highlight potentially modifiable contributors to inflammation.
BACKGROUND:HIV and hepatitis C virus (HCV) infections may increase interleukin-6 (IL-6) and C-reactive protein (CRP). However, relationships between inflammatory biomarkers, chronic viral infections, clinical factors, and behavioral factors remain poorly understood. METHODS: Using linear regression, we modeled cross-sectional associations between loge IL-6 or loge CRP levels and HCV, HIV, injection drug use, and comorbidity among 1191 injection drug users. RESULTS: Mean age was 47 years, 46.0% reported currently injecting drugs, 59.0% were HCV monoinfected, and 27% were HCV/HIV coinfected. In multivariable models, higher loge IL-6 was associated with HCV monoinfection [β = 0.191, 95% confidence interval (CI): 0.043 to 0.339] and HCV/HIV coinfection (β = 0.394, 95% CI: 0.214 to 0.574). In contrast, HCV monoinfection (β = -0.523, 95% CI: -0.275 to -0.789) and HCV/HIV coinfection (β = -0.554 95% CI: -0.260 to -0.847) were associated with lower CRP. Lower CRP with HCV infection was independent of liver fibrosis severity, synthetic function, or liver injury markers; CRP decreased with higher HCV RNA. Increased injection intensity was associated with higher IL-6 (P = 0.003) and CRP (P < 0.001); increasing comorbidity (P < 0.001) and older age (P = 0.028) were associated with higher IL-6; older age was associated with higher CRP among HCV-uninfectedparticipants (P = 0.021). CONCLUSION:HIV and HCV infections contribute to chronic inflammation; however, reduced CRP possibly occurs through HCV-mediated mechanisms. Findings highlight potentially modifiable contributors to inflammation.
Authors: Deborah L Regidor; Roger Detels; Elizabeth C Breen; Daniel P Widney; Lisa P Jacobson; Frank Palella; Charles R Rinaldo; Jay H Bream; Otoniel Martínez-Maza Journal: AIDS Date: 2011-01-28 Impact factor: 4.177
Authors: Matteo Cesari; Brenda W J H Penninx; Anne B Newman; Stephen B Kritchevsky; Barbara J Nicklas; Kim Sutton-Tyrrell; Russell P Tracy; Susan M Rubin; Tamara B Harris; Marco Pahor Journal: Am J Cardiol Date: 2003-09-01 Impact factor: 2.778
Authors: Giuseppe Castello; Stefania Scala; Giuseppe Palmieri; Steven A Curley; Francesco Izzo Journal: Clin Immunol Date: 2009-11-11 Impact factor: 3.969
Authors: Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow Journal: AIDS Date: 2016-01 Impact factor: 4.177
Authors: Álvaro H Borges; Jemma L O'Connor; Andrew N Phillips; Frederikke F Rönsholt; Sarah Pett; Michael J Vjecha; Martyn A French; Jens D Lundgren Journal: J Infect Dis Date: 2015-02-26 Impact factor: 5.226
Authors: Shailja Shah; Yifei Ma; Rebecca Scherzer; Greg Huhn; Audrey L French; Michael Plankey; Marion G Peters; Carl Grunfeld; Phyllis C Tien Journal: AIDS Date: 2015-07-17 Impact factor: 4.177
Authors: Damani A Piggott; Ravi Varadhan; Shruti H Mehta; Todd T Brown; Huifen Li; Jeremy D Walston; Sean X Leng; Gregory D Kirk Journal: J Gerontol A Biol Sci Med Sci Date: 2015-09-18 Impact factor: 6.053
Authors: Meredith Greene; Kenneth Covinsky; Jacquie Astemborski; Damani A Piggott; Todd Brown; Sean Leng; Noya Galai; Shruti H Mehta; Jack Guralnik; Kushang V Patel; Gregory D Kirk Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Sean X Leng; Stewart Dandorf; Huifen Li; Joshua Carlson; Jessica Hui; Shruti H Mehta; Damani Piggott; Salequl Islam; Bhavish Manwani; Gregory D Kirk Journal: AIDS Res Hum Retroviruses Date: 2015-10-13 Impact factor: 2.205
Authors: Heather S McKay; Jay H Bream; Joseph B Margolick; Otoniel Martínez-Maza; John P Phair; Charles R Rinaldo; Alison G Abraham; Lisa P Jacobson Journal: Cytokine Date: 2016-06-10 Impact factor: 3.861
Authors: Jose R Castillo-Mancilla; Mary Morrow; Yap Boum; Helen Byakwaga; Jessica E Haberer; Jeffrey N Martin; David Bangsberg; Samantha Mawhinney; Nicholas Musinguzi; Yong Huang; Russell P Tracy; Tricia H Burdo; Kenneth Williams; Conrad Muzzora; Peter W Hunt; Mark J Siedner Journal: J Acquir Immune Defic Syndr Date: 2018-04-15 Impact factor: 3.731